2025 Partners
Find out more about the companies who are partnering with the 8th RNA-Targeted Drug Discovery & Development Summit. Get in touch if you would like to partner with us in 2025, and learn more about our bespoke sponsorship opportunities.
PTC Therapeutics
Lead Partner
PTC is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults living with serious diseases of high unmet need. The alternative RNA splicing technology has broad potential to identify new treatments for many diseases. We believe that we can identify other small molecules that modify alternative splicing of genes, promote inclusion of specific exons, or force skipping of undesired exons from the mature mRNA. We continue to build on our alternative RNA splicing platform to develop innovative therapies that address the underlying causes of life-limiting diseases
Arrayjet
Expertise Partner
Arrayjet provides microarray screening solutions for researchers and drug discovery groups worldwide. Its Small Molecule Microarrays (SMM) are an effective platform for primary hit identification against RNA and protein targets.
Arrayjet microarray systems can be integrated into customer discovery operations, or screening can be fully outsourced to its CRO/CMO laboratory in Scotland, UK.
QSimulate
Hosting Partner
QSimulate is reshaping the Future of Computational Drug Discovery by providing revolutionary quantum-powered simulation solutions that reduce R&D timelines and increase the success of therapeutic candidates. Founded in 2019, QSimulate operates globally with offices in Boston, MA; Berkeley, CA; Ghent, Belgium; and Tokyo, Japan.
Lucerna
Innovation Partner
Momentum Biotechnologies, founded in 2014, is a drug discovery partner providing specialized mass spectrometry technologies to clients worldwide. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, proteomics / chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. In early 2025, Momentum expanded to Europe, where it operates as OmicScouts, a Momentum Biotechnologies Company.
Schrödinger
Industry Partner
Schrödinger is transforming molecular discovery with its computational platform, enabling the design of novel, optimized molecules for drug development and materials research. Built on over 30 years of R&D, the platform is used by biotechnology, pharmaceutical, industrial, and academic institutions worldwide. Schrödinger also advances a portfolio of collaborative and proprietary programs. Founded in 1990, the company has about 800 employees across 15 global locations. Learn more at www.schrodinger.com or on LinkedIn and Extrapolations.com.
Momentum Biotechnologies
Exhibition Partner
We share your passion for science. Promega Corporation is a world leader in providing innovative solutions for the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. Our broad life science portfolio includes biochemical and cell-based assays for drug discovery enabling research focused on hot targets like kinases, DDR/PARP, and RAS, and innovative modalities like induced proximity and targeting RNA. Let’s collaborate
Next Steps
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Oliver Smare
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com